Germany sustains diabetes vendetta with Jardiance no
This article was originally published in Scrip
Executive Summary
Germany's health technology appraisal body IQWiG is showing no signs of softening its approach to novel diabetes drugs, issuing yet another negative appraisal verdict, this time for Boehringer Ingelheim's Jardiance (empagliflozin).